Maurits C F J de Rotte1, Ethan den Boer1, Pascal H P de Jong2, Saskia M F Pluijm3, Maja Bulatović Ćalasan4, Angelique E Weel5, A Margriet Huisman6, Andreas H Gerards7, Barbara van Schaeybroeck8, Nico M Wulffraat4, Jan Lindemans1, Johanna M W Hazes2, Robert de Jonge1. 1. Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, Netherlands. 2. Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands. 3. Department of Pediatric Hemato-Oncology, Erasmus University Medical Center, Rotterdam, Netherlands. 4. Department of Pediatric Immunology, University Medical Center Utrecht, Wilhelmina Children's hospital, Utrecht, Netherlands. 5. Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands. 6. Interne Specialismen Rijnmond Noord, Sint Franciscus Hospital, Rotterdam and IJsselland Hospital, Capelle aan de IJssel, Netherlands. 7. Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands. 8. Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands.
Abstract
OBJECTIVE: To investigate if erythrocyte-methotrexate-polyglutamate (MTX-PG) concentrations in patients with rheumatoid arthritis (RA) are associated with disease activity or adverse events. METHODS: We used a longitudinal study design with two cohorts. The derivation cohort included 102 and the validation cohort included 285 patients with RA on MTX. We measured erythrocyte-MTX-PG with 1-5 glutamate residues at 3 months, 6 months and 9 months after MTX start with a liquid chromatography (LC)-mass spectrometry (MS)/MS assay. Outcomes were disease activity score in 28 joints (DAS28) and adverse events. Longitudinal associations of MTX-PG concentrations after 3 months, 6 months and 9 months with DAS28 were tested with a linear mixed model adjusted for age, gender, baseline DAS28, MTX dose and comedication. RESULTS: In the derivation cohort, mean DAS28 decreased from 4.26 (SE=0.14) at baseline to 2.72 (SE=0.13) after 9 months. Thirty per cent of patients in the derivation cohort experienced more than three adverse events after 3 months, which decreased to 18% after 9 months. In the validation cohort, DAS28 and adverse events were comparable with the derivation cohort. In the derivation cohort, MTX-PG1 (ß=-0.005), MTX-PG2 (ß=-0.022), MTX-PG3 (β=-0.007) and total MTX-PG (ß=-0.004) were associated (p<0.05) with lower DAS28 over 9 months. In the validation cohort, MTX-PG2 (ß=-0.015), MTX-PG3 (ß=-0.010), MTX-PG4 (ß=-0.008) and total MTX-PG (ß=-0.003) were associated with lower DAS28 over 9 months. None of the MTX-PGs was associated with adverse events. CONCLUSIONS: In this first longitudinal study, we showed that an increase in erythrocyte-MTX-PG concentration was associated with a decreased DAS28 over 9 months in two cohorts, and is therefore a potential tool for therapeutic drug monitoring of MTX in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To investigate if erythrocyte-methotrexate-polyglutamate (MTX-PG) concentrations in patients with rheumatoid arthritis (RA) are associated with disease activity or adverse events. METHODS: We used a longitudinal study design with two cohorts. The derivation cohort included 102 and the validation cohort included 285 patients with RA on MTX. We measured erythrocyte-MTX-PG with 1-5 glutamate residues at 3 months, 6 months and 9 months after MTX start with a liquid chromatography (LC)-mass spectrometry (MS)/MS assay. Outcomes were disease activity score in 28 joints (DAS28) and adverse events. Longitudinal associations of MTX-PG concentrations after 3 months, 6 months and 9 months with DAS28 were tested with a linear mixed model adjusted for age, gender, baseline DAS28, MTX dose and comedication. RESULTS: In the derivation cohort, mean DAS28 decreased from 4.26 (SE=0.14) at baseline to 2.72 (SE=0.13) after 9 months. Thirty per cent of patients in the derivation cohort experienced more than three adverse events after 3 months, which decreased to 18% after 9 months. In the validation cohort, DAS28 and adverse events were comparable with the derivation cohort. In the derivation cohort, MTX-PG1 (ß=-0.005), MTX-PG2 (ß=-0.022), MTX-PG3 (β=-0.007) and total MTX-PG (ß=-0.004) were associated (p<0.05) with lower DAS28 over 9 months. In the validation cohort, MTX-PG2 (ß=-0.015), MTX-PG3 (ß=-0.010), MTX-PG4 (ß=-0.008) and total MTX-PG (ß=-0.003) were associated with lower DAS28 over 9 months. None of the MTX-PGs was associated with adverse events. CONCLUSIONS: In this first longitudinal study, we showed that an increase in erythrocyte-MTX-PG concentration was associated with a decreased DAS28 over 9 months in two cohorts, and is therefore a potential tool for therapeutic drug monitoring of MTX in RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Hamid J Mohamed; Michael J Sorich; Stefan M Kowalski; Ross McKinnon; Susanna M Proudman; Leslie Cleland; Michael D Wiese Journal: Eur J Clin Pharmacol Date: 2015-02-18 Impact factor: 2.953
Authors: Arduino A Mangoni; Leena R Baghdadi; E Michael Shanahan; Michael D Wiese; Sara Tommasi; David Elliot; Richard J Woodman Journal: Ther Adv Musculoskelet Dis Date: 2017-08-01 Impact factor: 5.346
Authors: Rakesh K Singh; Leon van Haandel; Paul Kiptoo; Mara L Becker; Teruna J Siahaan; Ryan S Funk Journal: Eur J Pharmacol Date: 2019-04-02 Impact factor: 4.432
Authors: Gerd R Burmester; Gurjit S Kaeley; Arthur F Kavanaugh; Cem Gabay; Daryl K MacCarter; Peter Nash; Tsutomu Takeuchi; Sandra L Goss; Ramona Rodila; Kun Chen; Hartmut Kupper; Jasmina Kalabic Journal: RMD Open Date: 2017-09-17
Authors: Ryan Morrow; Ryan Funk; Mara Becker; Ashley Sherman; Leon Van Haandel; Taina Hudson; Rebecca Casini; Valentina Shakhnovich Journal: Pharmaceuticals (Basel) Date: 2021-05-14